Tin tức & Cập nhật

Galcanezumab a safer choice than prednisone for medication overuse headache

Both galcanezumab and prednisone effectively relieve pain in people with medication overuse headache (MOH), with combination therapy using both medications yielding the greatest benefit, according to the results of a three-arm, head-to-head observational study. However, the use of prednisone is accompanied by an increased frequency of adverse events.

Meta-analysis strengthens case for argatroban use in patients with END after stroke

Argatroban appears to reduce neurological deficits in acute ischaemic stroke (AIS) patients with early neurological deterioration (END) who are undergoing thrombolytic therapy, without increasing the risk of symptomatic intracranial haemorrhage, according to the results of a meta-analysis.

Ngày Thế giới về Não 22/07/2024

Bảo vệ sức khỏe não bộ - Bảo vệ tương lai

Não bộ là cơ quan quan trọng chi phối mọi hoạt động của cơ thể

Nipocalimab + SoC improves MG-ADL scores in adults with myasthenia gravis

Adding nipocalimab to standard-of-care (SoC) treatment significantly improves Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores in patients with generalized MG (gMG), according to the pivotal phase III Vivacity-MG3 study presented at EAN 2024.

Prenatal air pollution exposure tied to increased cerebral palsy risk

Prenatal exposure to fine particulate matter appears to put newborns at risk of cerebral palsy, as shown in a study.

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

Omaveloxolone slows neurological progression in earlier-onset Friedreich’s ataxia

The treatment effect of omaveloxolone in halting progression, based on change in mFARS score, is particularly pronounced in individuals with Friedreich's ataxia who had disease onset at ≤15 years of age, suggests a post hoc subgroup analysis of MOXIe Part 2 presented at EAN 2024.